Next Investors logo grey

Potential rerate for Starpharma as FDA clears way for VivaGel

Published 13-JAN-2017 13:50 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

While shares in Starpharma Holdings, a prominent global player in the development of dendrimer products for pharmaceutical, life sciences and other applications, have rallied strongly in the last three months, increasing from 60 cents to close at 76.5 cents yesterday, Bell Potter sees the scope for further upside, setting its share price target at $1.05.

It should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

On Thursday the company announced that it had been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel BV by the US Food and Drug Administration.

In highlighting the significance of this development, Starpharma’s Chief Executive, Doctor Jackie Fairley said, “VivaGel BV is understood to be the only product to receive such QIDP and FDA designations for both the BV treatment and prevention indications”.

Although the market responded positively to this news on Thursday with Starpharma being one of the few healthcare stocks to gain ground on a day which the sector was hammered, the response could arguably have been more pronounced if industry sentiment was less volatile.

Starpharma’s lead products are based on VivaGel, a proprietary dendrimer which has antimicrobial properties. The product formulated as a water based gel and delivered vaginally now has European Union regulatory approval for topical treatment and rapid relief of bacterial vaginosis (BV) and is under clinical development for the prevention of recurrent BV.

The group has also signed a license agreement with Aspen Pharmacare Australia for the sale and marketing of VivaGel in Australia and New Zealand. Separate license agreements have been negotiated with Ansell and other global condom manufacturers.

The VivaGel condom encompasses Starpharma’s BV product and is marketed in Australia and overseas under brands such as Dual Protect, LifeStyles, ZERO and SKYN.

In response to yesterday’s developments Bell Potter highlighted that the QIDP designation made VivaGel BV eligible for certain benefits which include an additional five years of market exclusivity over the standard exclusivity on marketing approval and priority review, which would shorten the FDA review time to 6 months as opposed to the standard 10 months.

The broker has a buy recommendation on the stock and the price target of $1.05 implies a premium of nearly 40% to yesterday’s closing price.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.